EA022096B1 - Соединения, подходящие для ингибирования chk1 - Google Patents
Соединения, подходящие для ингибирования chk1 Download PDFInfo
- Publication number
- EA022096B1 EA022096B1 EA201390499A EA201390499A EA022096B1 EA 022096 B1 EA022096 B1 EA 022096B1 EA 201390499 A EA201390499 A EA 201390499A EA 201390499 A EA201390499 A EA 201390499A EA 022096 B1 EA022096 B1 EA 022096B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- methoxy
- methylpyridin
- amine
- yloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41113710P | 2010-11-08 | 2010-11-08 | |
| PCT/US2011/058692 WO2012064548A1 (en) | 2010-11-08 | 2011-11-01 | Compounds useful for inhibiting chk1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201390499A1 EA201390499A1 (ru) | 2013-08-30 |
| EA022096B1 true EA022096B1 (ru) | 2015-10-30 |
Family
ID=45044707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390499A EA022096B1 (ru) | 2010-11-08 | 2011-11-01 | Соединения, подходящие для ингибирования chk1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9067920B2 (https=) |
| EP (1) | EP2638033B1 (https=) |
| JP (1) | JP5792316B2 (https=) |
| KR (1) | KR101533166B1 (https=) |
| CN (1) | CN103180311B (https=) |
| AR (1) | AR083575A1 (https=) |
| AU (1) | AU2011326230B2 (https=) |
| BR (1) | BR112013010009B1 (https=) |
| CA (1) | CA2816944C (https=) |
| DK (1) | DK2638033T3 (https=) |
| EA (1) | EA022096B1 (https=) |
| ES (1) | ES2541414T3 (https=) |
| HR (1) | HRP20150530T1 (https=) |
| JO (1) | JO3145B1 (https=) |
| ME (1) | ME02119B (https=) |
| MX (1) | MX2013005181A (https=) |
| PL (1) | PL2638033T3 (https=) |
| PT (1) | PT2638033E (https=) |
| RS (1) | RS54012B1 (https=) |
| SI (1) | SI2638033T1 (https=) |
| TW (1) | TWI501956B (https=) |
| WO (1) | WO2012064548A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| HRP20220351T1 (hr) | 2016-02-04 | 2022-05-13 | Pharmaengine, Inc. | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| AU2021389190A1 (en) | 2020-11-30 | 2023-06-29 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1h-pyrazol-3-amine derivative |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| US20250129049A1 (en) * | 2021-12-24 | 2025-04-24 | Sumitomo Pharma Co., Ltd. | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| US20250352541A1 (en) * | 2022-05-27 | 2025-11-20 | Sumitomo Pharma Co., Ltd. | Therapeutic for cancer refractory to immune checkpoint inhibitor |
| TW202442234A (zh) * | 2023-04-14 | 2024-11-01 | 美商纜圖藥品公司 | Ｃｄｋ２抑制劑 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009435A1 (en) * | 2003-07-25 | 2005-02-03 | Pfizer Inc. | Aminopyrazole compounds and use as chk1 inhibitors |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0418351A (pt) * | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
| CN101218229A (zh) * | 2005-05-05 | 2008-07-09 | 阿斯利康(瑞典)有限公司 | 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用 |
| AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
-
2011
- 2011-10-27 JO JOP/2011/0323A patent/JO3145B1/ar active
- 2011-10-27 AR ARP110103973A patent/AR083575A1/es active IP Right Grant
- 2011-10-28 TW TW100139492A patent/TWI501956B/zh active
- 2011-11-01 EA EA201390499A patent/EA022096B1/ru not_active IP Right Cessation
- 2011-11-01 WO PCT/US2011/058692 patent/WO2012064548A1/en not_active Ceased
- 2011-11-01 AU AU2011326230A patent/AU2011326230B2/en active Active
- 2011-11-01 SI SI201130467T patent/SI2638033T1/sl unknown
- 2011-11-01 US US13/877,923 patent/US9067920B2/en active Active
- 2011-11-01 KR KR1020137011808A patent/KR101533166B1/ko active Active
- 2011-11-01 JP JP2013537756A patent/JP5792316B2/ja active Active
- 2011-11-01 CA CA2816944A patent/CA2816944C/en active Active
- 2011-11-01 EP EP11788263.9A patent/EP2638033B1/en active Active
- 2011-11-01 DK DK11788263T patent/DK2638033T3/en active
- 2011-11-01 RS RS20150352A patent/RS54012B1/sr unknown
- 2011-11-01 BR BR112013010009-5A patent/BR112013010009B1/pt active IP Right Grant
- 2011-11-01 ME MEP-2015-69A patent/ME02119B/me unknown
- 2011-11-01 HR HRP20150530TT patent/HRP20150530T1/hr unknown
- 2011-11-01 MX MX2013005181A patent/MX2013005181A/es active IP Right Grant
- 2011-11-01 CN CN201180053779.8A patent/CN103180311B/zh active Active
- 2011-11-01 PT PT117882639T patent/PT2638033E/pt unknown
- 2011-11-01 PL PL11788263T patent/PL2638033T3/pl unknown
- 2011-11-01 ES ES11788263.9T patent/ES2541414T3/es active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009435A1 (en) * | 2003-07-25 | 2005-02-03 | Pfizer Inc. | Aminopyrazole compounds and use as chk1 inhibitors |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011326230A1 (en) | 2013-05-09 |
| EP2638033A1 (en) | 2013-09-18 |
| JP5792316B2 (ja) | 2015-10-07 |
| EA201390499A1 (ru) | 2013-08-30 |
| CA2816944C (en) | 2015-12-22 |
| KR101533166B1 (ko) | 2015-07-01 |
| BR112013010009B1 (pt) | 2021-10-19 |
| CN103180311A (zh) | 2013-06-26 |
| DK2638033T3 (en) | 2015-04-27 |
| BR112013010009A2 (pt) | 2020-09-29 |
| PT2638033E (pt) | 2015-06-01 |
| JO3145B1 (ar) | 2017-09-20 |
| EP2638033B1 (en) | 2015-04-08 |
| CA2816944A1 (en) | 2012-05-18 |
| TWI501956B (zh) | 2015-10-01 |
| AR083575A1 (es) | 2013-03-06 |
| CN103180311B (zh) | 2014-08-20 |
| JP2013541586A (ja) | 2013-11-14 |
| ME02119B (me) | 2015-10-20 |
| US20130190262A1 (en) | 2013-07-25 |
| HRP20150530T1 (hr) | 2015-06-19 |
| US9067920B2 (en) | 2015-06-30 |
| WO2012064548A1 (en) | 2012-05-18 |
| RS54012B1 (sr) | 2015-10-30 |
| PL2638033T3 (pl) | 2015-09-30 |
| ES2541414T3 (es) | 2015-07-20 |
| KR20130099146A (ko) | 2013-09-05 |
| SI2638033T1 (sl) | 2015-05-29 |
| AU2011326230B2 (en) | 2015-02-19 |
| TW201305138A (zh) | 2013-02-01 |
| MX2013005181A (es) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA022096B1 (ru) | Соединения, подходящие для ингибирования chk1 | |
| CN113614083B (zh) | 咪唑酮基喹啉化合物及其治疗用途 | |
| KR20230173083A (ko) | Cdk 억제제 및 이의 사용 방법 | |
| RU2743343C2 (ru) | Имидазолонилхинолины и их применение в качестве ингибиторов киназы атм | |
| KR101398268B1 (ko) | Ａｋｔ 억제제 | |
| AU2018255191A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| JP2013529212A (ja) | ｍＴＯＲ選択的キナーゼ阻害剤 | |
| WO2021064141A1 (en) | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b | |
| WO2019057757A1 (en) | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| WO2017070565A1 (en) | Heterocyclic pdk1 inhibitors for use to treat cancer | |
| CA3130478A1 (en) | Heteroaryl derivatives, and pharmaceutical composition comprising the same as active ingredient | |
| CN112292379B (zh) | 吡啶并吡啶酮衍生物的盐型及晶型 | |
| RU2822479C2 (ru) | Соединения имидазолонилхинолина и их терапевтическое применение | |
| WO2025101588A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |